Landos Biopharma Inc. (LABP)
NASDAQ: LABP
· Real-Time Price · USD
22.93
0.13 (0.57%)
At close: May 23, 2024, 10:00 PM
Landos Biopharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -18M | n/a | 18M | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 224K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -224K | n/a | -18M | n/a | 18M | n/a |
Operating Income | -9.29M | -6.31M | -5.2M | -4.44M | -6.48M | -6.51M | -7.83M | -11.27M | -14.95M | -20.4M | -12.4M | 3.88M | -9.9M |
Interest Income | 401K | n/a | n/a | n/a | 449K | n/a | n/a | n/a | n/a | 320K | n/a | 179K | n/a |
Pretax Income | -8.9M | -6.12M | -5.86M | -3.92M | -6.03M | -5.23M | -7.9M | -11.28M | -14.86M | -20.1M | -12.6M | 4.1M | -9.82M |
Net Income | -8.9M | -6.12M | -5.86M | -3.92M | -5.59M | -3.88M | -7.96M | -11.3M | -14.78M | -20.1M | -12.6M | 4.1M | -9.82M |
Selling & General & Admin | 6.14M | 3.16M | 2.14M | 1.98M | 3.15M | 3.1M | 2.97M | 4.66M | 4.15M | 6.95M | 3.06M | 2.6M | 2.65M |
Research & Development | 3.15M | 3.15M | 3.06M | 2.46M | 3.33M | 3.41M | 4.86M | 6.6M | 10.8M | 13.44M | 9.34M | 11.52M | 7.25M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | -67K | -43K | 88K | n/a | n/a | 41K | 64K |
Operating Expenses | 9.29M | 6.31M | 5.2M | 4.44M | 6.48M | 6.51M | 7.83M | 11.27M | 14.95M | 20.4M | 12.4M | 14.12M | 9.9M |
Interest Expense | n/a | 546K | n/a | 557K | n/a | n/a | 67K | n/a | n/a | 320K | 191K | n/a | n/a |
Selling & Marketing Expenses | n/a | -300K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.29M | 6.31M | 5.2M | 4.44M | 6.48M | 6.51M | 7.83M | 11.27M | 14.95M | 20.4M | 12.4M | 14.12M | 9.9M |
Income Tax Expense | n/a | n/a | n/a | n/a | -445K | -1.35M | 67K | 18K | -89K | n/a | n/a | n/a | 64K |
Shares Outstanding (Basic) | 6.21M | 6.21M | 6.21M | 6.21M | 6.48M | 4.03M | 4.03M | 4.03M | 4.03M | 4.02M | 4M | 3.36M | 2.61M |
Shares Outstanding (Diluted) | 6.21M | 6.21M | 6.21M | 6.21M | 6.48M | 4.03M | 4.03M | 4.03M | 4.03M | 4.02M | 4M | 3.44M | 2.61M |
EPS (Basic) | -1.43 | -0.99 | -0.94 | -0.63 | -0.86 | -0.96 | -1.98 | -2.81 | -3.67 | -5.2 | -3.2 | 1.20 | -3.8 |
EPS (Diluted) | -1.43 | -0.99 | -0.94 | -0.63 | -0.86 | -0.96 | -1.98 | -2.81 | -3.67 | -5.2 | -3.2 | 1.20 | -3.8 |
EBITDA | -9.29M | -6.31M | -5.2M | -4.4M | -6.47M | -6.51M | -7.83M | -11.07M | -14.6M | -20.32M | -12.36M | 3.94M | -9.79M |
EBIT | -9.29M | -5.57M | -6.52M | -3.37M | -6.48M | -8.24M | -7.83M | -11.31M | -14.87M | -19.78M | -12.41M | 3.88M | -9.9M |
Depreciation & Amortization | 43.28K | 12K | -39.59K | 40K | 4K | -581K | 27.08K | 199K | 352K | 55K | 48K | 50K | 43K |